<DOC>
	<DOCNO>NCT00966576</DOCNO>
	<brief_summary>The purpose study assess safety efficacy add AZARGA glaucoma patient uncontrolled intraocular pressure ( IOP ) , currently prostaglandin monotherapy .</brief_summary>
	<brief_title>Efficacy Safety Adding Azarga Prostaglandin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Sign Informed Consent . 21 year age old . Able follow instruction willing attend require study visit . Clinical diagnosis ocular hypertension , primary openangle , pigment dispersion glaucoma least one eye ( qualify eye ) . Intraocular pressure ( IOP ) consider safe eye way assure clinical stability vision optic nerve throughout trial . Must best correct visual acuity 6/60 ( 6/60 Snellen , 1.0 LogMAR ) good eye . Other protocoldefined inclusion criterion may apply . Presence primary secondary glaucoma list inclusion criterion . Presence corneal dystrophy . Concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye . Intraocular conventional surgery laser surgery qualify eye ( ) less three month prior Visit 1 . Risk visual field visual acuity worsen consequence participation trial , investigator 's best judgment . Women childbearing potential use reliable mean birth control . Women pregnant lactating . Participation investigational study within 30 day prior Visit 1 . Current anticipate use systemic corticosteroid , route except inhale , great two week trial . Severe allergic rhinitis History ocular herpes simplex . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>IOP</keyword>
	<keyword>AZARGA</keyword>
</DOC>